Basmisanil

Basmisanil

Clinical data
ATC code	None
Identifiers
IUPAC name (1,1-Dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone
CAS Number	1159600-41-5
PubChem CID	57336276
ChemSpider	34500832
KEGG	D10863 Y
Chemical and physical data
Formula	C21H20FN3O5S
Molar mass	445.464003 g/mol
3D model (JSmol)	Interactive image
SMILES CC1=C(C(=NO1)C2=CC=C(C=C2)F)COC3=NC=C(C=C3)C(=O)N4CCS(=O)(=O)CC4
InChI InChI=1S/C21H20FN3O5S/c1-14-18(20(24-30-14)15-2-5-17(22)6-3-15)13-29-19-7-4-16(12-23-19)21(26)25-8-10-31(27,28)11-9-25/h2-7,12H,8-11,13H2,1H3 Key:VCGRFBXVSFAGGA-UHFFFAOYSA-N

Basmisanil (INN) (developmental code names RG-1662, RO5186582) is a highly selective inverse agonist/negative allosteric modulator of α₅ subunit-containing GABA_A receptors which is under development by Roche for the treatment of cognitive impairment associated with Down syndrome. As of August 2015, it is in phase II clinical trials for this indication.